Depakene/Depakote/ Depakote
... Depakene (valproic acid) and Depakote (divalproex sodium) are better known as anticonvulsants—medications for treating epilepsy. This may present some confusion for patients, as well as their families, when they are prescribed an anticonvulsant without a history of seizures. In the past decade, anti ...
... Depakene (valproic acid) and Depakote (divalproex sodium) are better known as anticonvulsants—medications for treating epilepsy. This may present some confusion for patients, as well as their families, when they are prescribed an anticonvulsant without a history of seizures. In the past decade, anti ...
TCCC Change Prop 1403 Ondansetron 150403 JSOM
... Since September 16, 2009, there has been an FDA Black Box Warning for the injectable form of promethazine due to “the risk of serious tissue injury when this drug is administered incorrectly.”17 Foret, et al, report two cases of accidental intra-arterial promethazine injection that led to necrosis, ...
... Since September 16, 2009, there has been an FDA Black Box Warning for the injectable form of promethazine due to “the risk of serious tissue injury when this drug is administered incorrectly.”17 Foret, et al, report two cases of accidental intra-arterial promethazine injection that led to necrosis, ...
AusPAR: Pitavastatin - Therapeutic Goods Administration
... Risk-benefit analysis ______________________________________________________________ 122 ...
... Risk-benefit analysis ______________________________________________________________ 122 ...
Pr VIAGRA*
... Patients should stop taking PDE5 inhibitors, including VIAGRA, and consult their physician immediately if they experience a decrease in, or sudden loss of, vision in one or both eyes. Postmarketing reports of sudden loss of vision have occurred rarely, in temporal association with the use of PDE5 in ...
... Patients should stop taking PDE5 inhibitors, including VIAGRA, and consult their physician immediately if they experience a decrease in, or sudden loss of, vision in one or both eyes. Postmarketing reports of sudden loss of vision have occurred rarely, in temporal association with the use of PDE5 in ...
Product Monograph
... 50 mg/day: 26%; 100 mg/day: 41%). Pediatric patients under two years of age who were treated with adjunctive topiramate for partial onset epilepsy, also experienced hyperammonemia (placebo: 8%; 5 mg/kg/day: 10%; 15 mg/kg/day: 0%; 25 mg/kg/day: 9%). TOPAMAX® is not indicated for migraine prophylaxis ...
... 50 mg/day: 26%; 100 mg/day: 41%). Pediatric patients under two years of age who were treated with adjunctive topiramate for partial onset epilepsy, also experienced hyperammonemia (placebo: 8%; 5 mg/kg/day: 10%; 15 mg/kg/day: 0%; 25 mg/kg/day: 9%). TOPAMAX® is not indicated for migraine prophylaxis ...
Martindale: The Complete Drug Reference
... Uses and Administration (Latest modification: 05-Sep-2009) Cefuroxime is a second-generation cephalosporin antibacterial used in the treatment of infections caused by susceptible Gram-positive and Gram-negative bacteria, including infections of the bones and joints, CNS, skin and skin structures, re ...
... Uses and Administration (Latest modification: 05-Sep-2009) Cefuroxime is a second-generation cephalosporin antibacterial used in the treatment of infections caused by susceptible Gram-positive and Gram-negative bacteria, including infections of the bones and joints, CNS, skin and skin structures, re ...
Biol. Pharm. Bull. 34(8): 1179
... could self-emulsify under dilution and gentle agitation. In brief, a series of SEDDS were prepared with varying concentrations of Lauroglycol Fcc (5—40% w/w), Labrasol (20— 90% w/w) and Transcutol HP (0—75% w/w). Then, 0.2 ml of each formulation was added in a drop-wise manner to a beaker containing ...
... could self-emulsify under dilution and gentle agitation. In brief, a series of SEDDS were prepared with varying concentrations of Lauroglycol Fcc (5—40% w/w), Labrasol (20— 90% w/w) and Transcutol HP (0—75% w/w). Then, 0.2 ml of each formulation was added in a drop-wise manner to a beaker containing ...
Linköping University Post Print rivaroxaban on commonly used coagulation
... overdosing is another possible indication for testing. Furthermore, in bleeding patients on rivaroxaban treatment, it would be helpful to know if the drug is present or not in cases where it may be considered to try to use reversal agents, although there are not yet any established antidotes. There ...
... overdosing is another possible indication for testing. Furthermore, in bleeding patients on rivaroxaban treatment, it would be helpful to know if the drug is present or not in cases where it may be considered to try to use reversal agents, although there are not yet any established antidotes. There ...
PRODUCT MONOGRAPH PrMONUROL® Fosfomycin powder, 3g
... MONUROL (fosfomycin tromethamine), a phosphoric acid derivative is the mono-acid salt of fosfomycin with tromethamine. Fosfomycin is bactericidal in urine at therapeutic doses. Its bactericidal action is due to inactivation of the enzyme enolpyruvyl transferase, thereby blocking the condensation of ...
... MONUROL (fosfomycin tromethamine), a phosphoric acid derivative is the mono-acid salt of fosfomycin with tromethamine. Fosfomycin is bactericidal in urine at therapeutic doses. Its bactericidal action is due to inactivation of the enzyme enolpyruvyl transferase, thereby blocking the condensation of ...
Tramadol - Medsafe
... slightly prolonged. Patients in this age group are also expected to vary more widely in their ability to tolerate adverse drug effects. Daily doses of more than 300 mg are not recommended in patients over 75 years. Renal insufficiency Impaired renal function results in a decreased rate and extent of ...
... slightly prolonged. Patients in this age group are also expected to vary more widely in their ability to tolerate adverse drug effects. Daily doses of more than 300 mg are not recommended in patients over 75 years. Renal insufficiency Impaired renal function results in a decreased rate and extent of ...
Macrolides and ketolides: azithromycin, clarithromycin, telithromycin * Jerry M. Zuckerman, MD
... The macrolides and ketolides are lipophilic and are extensively distributed in body fluids and tissues. Mean tissue concentrations are 2- to 20-fold greater than serum concentrations for clarithromycin and are 10- to 100fold greater than serum concentrations for azithromycin [14,26]. Tissue concentra ...
... The macrolides and ketolides are lipophilic and are extensively distributed in body fluids and tissues. Mean tissue concentrations are 2- to 20-fold greater than serum concentrations for clarithromycin and are 10- to 100fold greater than serum concentrations for azithromycin [14,26]. Tissue concentra ...
product monograph
... Patients with uncontrolled epilepsy should not drive or handle potentially dangerous machinery. During clinical trials, the most common adverse reactions observed were somnolence, ataxia, fatigue, and nystagmus. Patients should be advised to refrain from activities requiring mental alertness or phys ...
... Patients with uncontrolled epilepsy should not drive or handle potentially dangerous machinery. During clinical trials, the most common adverse reactions observed were somnolence, ataxia, fatigue, and nystagmus. Patients should be advised to refrain from activities requiring mental alertness or phys ...
03-A922-R2 Erythromycin Tablets PI - 3-25-14
... contact their physician as soon as possible. Drug Interactions Theophylline Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated ...
... contact their physician as soon as possible. Drug Interactions Theophylline Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated ...
Version 7
... As may be expected agents as buspirone used in patients with a reduced liver function show a reduced “first pass effect”. After a single administration to patients with liver cirrhosis, higher maximum concentrations of unchanged buspirone are seen, with an increase in the half life time. In these pa ...
... As may be expected agents as buspirone used in patients with a reduced liver function show a reduced “first pass effect”. After a single administration to patients with liver cirrhosis, higher maximum concentrations of unchanged buspirone are seen, with an increase in the half life time. In these pa ...
PROPECIA
... Caution should be used in the administration of PROPECIA® in patients with liver function abnormalities, as finasteride is metabolized in the liver. Other causes of alopecia should be ruled out prior to prescribing PROPECIA®. Efficacy and duration of treatment should be assessed periodically by the ...
... Caution should be used in the administration of PROPECIA® in patients with liver function abnormalities, as finasteride is metabolized in the liver. Other causes of alopecia should be ruled out prior to prescribing PROPECIA®. Efficacy and duration of treatment should be assessed periodically by the ...
Intranasal (IN) Medication Administration MBED Clinical Practice
... Medications most commonly administered via the IN route are: fentanyl for pain and midazolam (Versed) for anxiolysis/mild sedation. Additionally, other medications may be administered by this route (see Dosing Guideline Chart below). Dosing is ordered in mg/kg, except for fentanyl and Precedex which ...
... Medications most commonly administered via the IN route are: fentanyl for pain and midazolam (Versed) for anxiolysis/mild sedation. Additionally, other medications may be administered by this route (see Dosing Guideline Chart below). Dosing is ordered in mg/kg, except for fentanyl and Precedex which ...
Timolol Maleate Ophthalmic Solution, USP 0.25% and 0.5%
... The maximum effect usually occurs in one to two hours and significant lowering of intraocular pressure can be maintained for periods as long as 24 hours with a single dose. Repeated observations over a period of one year indicate that the intraocular pressure-lowering effect of timolol is well maint ...
... The maximum effect usually occurs in one to two hours and significant lowering of intraocular pressure can be maintained for periods as long as 24 hours with a single dose. Repeated observations over a period of one year indicate that the intraocular pressure-lowering effect of timolol is well maint ...
ZOFRAN Tablets, Oral Solution and Injection PRODUCT MONOGRAPH
... neurotransmitter system is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see DRUG INTERACTIONS). Hepatic/Biliary/Pancreatic There is no experience in patients who are clinically jaundiced. The clearance of an 8 mg in ...
... neurotransmitter system is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see DRUG INTERACTIONS). Hepatic/Biliary/Pancreatic There is no experience in patients who are clinically jaundiced. The clearance of an 8 mg in ...
PrZOFRAN® Tablets, Oral Solution and Injection PrZOFRAN® ODT
... system is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see DRUG INTERACTIONS). Hepatic/Biliary/Pancreatic There is no experience in patients who are clinically jaundiced. The clearance of an 8 mg intravenous dose of ...
... system is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see DRUG INTERACTIONS). Hepatic/Biliary/Pancreatic There is no experience in patients who are clinically jaundiced. The clearance of an 8 mg intravenous dose of ...
product monograph
... RISPERDAL CONSTA® may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, syncope, probably reflecting its alpha-adrenergic antagonistic properties. Syncope was reported in 0.8% (12/1499) of patients treated with RISPERDAL CONSTA® in repeated-dose studies. Cl ...
... RISPERDAL CONSTA® may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, syncope, probably reflecting its alpha-adrenergic antagonistic properties. Syncope was reported in 0.8% (12/1499) of patients treated with RISPERDAL CONSTA® in repeated-dose studies. Cl ...
CLINDAMYCIN Phosphate CLINDAMYCIN Hydrochloride
... distributed in body fluids and tissues (including bones). The average biological half-life is 2.4 hours. Approximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as bioinactive metabolites. Doses ...
... distributed in body fluids and tissues (including bones). The average biological half-life is 2.4 hours. Approximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as bioinactive metabolites. Doses ...
Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended
... Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may produce dose-related respiratory depression by acting directly on brain stem respiratory centers (see OVERDOSAGE). Use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspensio ...
... Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may produce dose-related respiratory depression by acting directly on brain stem respiratory centers (see OVERDOSAGE). Use of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspensio ...
The poster sessions are an important highlight of these conferences
... Rationale: Inno-406 is an oral dual ABL/Lyn KI, which is up to 55 times more potent than IM. Numerous BLC ABL mutant proteins are sensitive to INNO 406 in vitro including the F317L mutant (Personal note from CAS: important note, this mutant is not sensitive or at least only very mildly sensitive to ...
... Rationale: Inno-406 is an oral dual ABL/Lyn KI, which is up to 55 times more potent than IM. Numerous BLC ABL mutant proteins are sensitive to INNO 406 in vitro including the F317L mutant (Personal note from CAS: important note, this mutant is not sensitive or at least only very mildly sensitive to ...
alertec - Shire Canada
... underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating ALERTEC. If ALERTEC is used adjunctively with CPAP, the encouragement of, and periodic ...
... underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating ALERTEC. If ALERTEC is used adjunctively with CPAP, the encouragement of, and periodic ...
1. name of the medicinal product
... The benefits of inhaled fluticasone propionate therapy should minimise the need for oral steroids, but patients transferring from oral steroids may remain at risk of impaired adrenal reserve for a considerable time. Therefore these patients should be treated with special care and adrenocortical func ...
... The benefits of inhaled fluticasone propionate therapy should minimise the need for oral steroids, but patients transferring from oral steroids may remain at risk of impaired adrenal reserve for a considerable time. Therefore these patients should be treated with special care and adrenocortical func ...
Dydrogesterone
Dydrogesterone (INN, USAN, BAN), is also chemically known as 9β,10α-pregna-4,6-diene-3,20-dione. Dydrogesterone (6-dehydro-retroprogesterone) is a hormonally active, non-androgenic steroid that was developed in the 1950s.Dydrogesterone has selective progestational activity and does not inhibit ovulation. The greater rigidity of dydrogesterone also positively affects its selectivity, while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. As a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10–20 times lower than that of oral micronized progesterone.Dydrogesterone is used as an effective, orally active progestogen for gynaecological conditions related to a wide variety of progesterone deficiencies in pregnant women. The molecular structure and pharmacological effects are somewhat similar to endogenous progesterone, although in smaller amounts it is found to be orally active. Its freedom from hormonal effects like those related to corticoid, androgenic, estrogenic, anabolic, and other effects gives dydrogesterone an advantage over other synthesized progestogens.Dydrogesterone when used therapeutically is closely related to its physiological action on the neuro-endocrine control of ovarian function, as well as on the endometrium. This is an indication in all cases of endogeneous progesterone deficiency - relative or absolute. The molecule was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhoea, irregular cycles, pre-menstrual syndrome and also as a hormone replacement therapy.Dydrogesterone has proven effective in the following conditions associated with progesterone deficiency: Infertility due to luteal insufficiency Threatened miscarriage Habitual or recurrent miscarriage. Menstrual disorders Premenstrual syndrome Endometriosis Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counter-check the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone acetate.